Patent SG-11201807590S-A (SG)
Title: Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
Inventor: MAURER DOMINIK
IPC: C07K14/725
Filed: 2017-03-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/158116 Al 21 September 2017 (21.09.2017) WIPO I PCT 111111111111110111011111111111010111110 011111111H 011101111111111111111110111111 (51) International Patent Classification: C07K 14/725 (2006.01) C07K 14/74 (2006.01) A61K 39/00 (2006.01) C12N 5/0783 (2010.01) (21) International Application Number: PCT/EP2017/056289 (22) International Filing Date: 16 March 2017 (16.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1604494.3 16 March 2016 (16.03.2016) GB 62/308,970 16 March 2016 (16.03.2016) US (71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH [DE/DE]; Paul-Ehrlich-StraBe 15, 72076 Tilbingen (DE). (72) Inventors: MAURER, Dominik; Fleinerweg 7, 72116 Moessingen (DE). ALTEN, Leonie; WeiBdomweg 14, App. 161, 72076 Tilbingen (DE). BUNK, Sebastian; Staeudach 182, 72074 Tilbingen (DE). (74) Agent: BOEHMERT & BOEHMERT; Jan B. KRAUSS, Pettenkoferstrasse 22, 80336 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 17 / 15 8 116 Al (54) Title: TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS (57) : The present description relates to T-cell receptors (TCRs) binding to tumor- associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 have the amino acid sequence of KIQEILTQV (SEQ ID NO:1). The present description further relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tu- mor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate an - ti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histo - compatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding mo - lecules.